Core Insights - Annovis Bio, Inc. is advancing its clinical pipeline with the investigational oral therapy, buntanetap, targeting neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1][2] - A recent article published in The Scientist details the history and development of buntanetap, highlighting its journey from discovery to its current Phase 3 clinical trials [2][3] Company Overview - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company based in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases [5] - The lead drug candidate, buntanetap, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism [5] Clinical Development - Buntanetap is currently being evaluated in a pivotal Phase 3 study for early AD, with 70% of patients enrolled, and in an open-label extension study for PD, with 20% of patients enrolled [2] - The article in The Scientist provides context for understanding the scientific journey of buntanetap, including its mechanism of action and the challenges faced during its development [2][3] Scientific Communication - The publication reflects Annovis' commitment to scientific transparency and education as it approaches important clinical and regulatory milestones [3] - The Scientist serves as a trusted platform for communicating advances in biology, medicine, and drug development, catering to life science professionals and researchers [3]

Core Insights - Annovis Bio, Inc. has announced a partnership with NeuroRPM to implement an FDA-cleared AI platform for monitoring Parkinson's disease symptoms in its ongoing clinical study of the investigational therapy, buntanetap [1][2]. Company Overview - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease [9]. - The lead drug candidate, buntanetap, is an investigational oral therapy aimed at inhibiting neurotoxic proteins to halt disease progression and improve cognitive and motor functions [9]. Partnership Details - The partnership with NeuroRPM aims to enhance data collection and monitoring in the open-label study (ANVS-25002) currently enrolling participants across 25 sites in the U.S. [2][6]. - NeuroRPM's AI-enabled medical device will monitor primary Parkinson's symptoms such as bradykinesia, tremor, and dyskinesia, providing real-time digital biomarkers [2][4]. Study Progress - The ANVS-25002 study has enrolled 90 out of an estimated total of 500 patients, with the study duration set for 36 months [6]. - Participants may have the option to continue using NeuroRPM technology for clinical monitoring after the study [6]. Technological Innovations - NeuroRPM's platform allows for continuous wearable monitoring, providing objective measurements of treatment response in real-world settings [5][7]. - The study will also utilize a highly accurate biomarker test for misfolded phosphorylated alpha-synuclein, which has over 90% diagnostic sensitivity and specificity [5]. Benefits of Digital Biomarkers - The collaboration is expected to yield data-driven insights that will enhance the understanding of disease progression and inform future clinical trial designs [3][5]. - The combination of digital and biological biomarkers aims to comprehensively record patient responses to treatment, improving the precision of outcome measurements [5].

Core Insights - Annovis Bio, Inc. is advancing its investigational oral therapy, buntanetap, for neurodegenerative diseases, achieving significant milestones in clinical development during 2025 [1][2] Clinical Progress - In 2025, Annovis initiated a pivotal Phase 3 clinical trial for early Alzheimer's disease (AD) and launched an open-label extension (OLE) study for Parkinson's disease (PD) [2][3] - The Phase 3 study for AD began in February 2025, with the first participants reaching a 6-month milestone by October 2025, showing potential disease-modifying activity through reductions in neurotoxic biomarkers [7] - As of March 2026, 65% of the target participant population for the Phase 3 AD trial has been enrolled across 83 clinical sites in the U.S. [7] - New biomarker data indicated that buntanetap improved cognition in PD patients and reduced amyloid and tau pathology [7] Business Highlights - Annovis transferred all patents to a new crystal form of buntanetap in August 2025, extending intellectual property protection until 2047 [11] - The company held 40 granted patents and 48 patent applications as of year-end 2025, with most patents approved in major global markets [11] - Annovis participated in key scientific conferences and investor events throughout 2025, enhancing its visibility in the biopharma sector [11] Financial Results - Research and development expenses for 2025 were $25.2 million, up from $20.0 million in 2024, while general and administrative expenses decreased to $4.5 million from $6.7 million [10][19] - Annovis reported a net loss of $28.9 million for 2025, with a basic and diluted net loss per share of $1.40, compared to a net loss of $24.6 million in 2024 [10][19] - Cash and cash equivalents increased to $19.5 million as of December 31, 2025, compared to $10.6 million in 2024, providing funding into the third quarter of 2026 [10][19]

Product Development - The company is developing its lead product candidate, buntanetap, targeting neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) with a focus on inhibiting neurotoxic proteins [439]. - The pivotal Phase 3 AD Trial initiated in February 2025 involves 760 early AD patients, with a 6-month treatment period followed by an additional 12 months to assess disease-modifying efficacy [442]. - The Phase 3 PD Trial was completed on December 4, 2023, showing that buntanetap improved UPDRS scores and stopped cognitive decline in 12% of patients with existing cognitive issues [449]. - The Phase 2/3 AD Trial completed on February 13, 2024, demonstrated that buntanetap improved ADAS-Cog11 scores in early AD patients in a statistically significant manner [450]. - The FDA has aligned with the company on a development path for buntanetap towards filing NDAs for both short-term and long-term efficacy [451]. - The company is refining the proposed protocol for a study in Parkinson's disease dementia (PDD) and plans to initiate the study contingent on additional funding [445]. - The company has completed 12 clinical studies, including two Phase 1/2 studies in early AD and PD patients, which showed improvements in cognition and function [446]. Financial Performance - The company has incurred a net loss of $163.7 million as of December 31, 2025, and expects losses to continue as it develops and seeks regulatory approvals for its product candidates [453]. - Total operating expenses for the year ended December 31, 2025, were $29.7 million, an increase of $3.0 million from $26.7 million in 2024 [464]. - Research and development expenses rose by $5.2 million to $25.2 million in 2025, primarily due to increased costs associated with Phase 3 AD Trial patients [465]. - General and administrative expenses decreased by $2.2 million to $4.5 million in 2025, mainly due to a reduction in stock-based compensation and other costs [466]. - Cash used in operating activities was $25.6 million in 2025, compared to $21.9 million in 2024, reflecting increased clinical trial expenses [484]. - The company expects to incur significant operating losses for the foreseeable future as it ramps up clinical development programs [478]. - As of December 31, 2025, the company's cash and cash equivalents totaled $19.5 million, which may not be sufficient to fund operations for the next 12 months [470][477]. - The company anticipates needing to raise substantial additional capital to complete the development and commercialization of its product candidates [477]. Research and Development Expenses - Research and development expenses in 2025 were primarily related to the Phase 3 AD Trial, with expectations for elevated expenses in 2026 due to ongoing clinical trials and potential NDA filings [459]. - Research and development expenses include costs related to clinical trials and regulatory compliance, with estimates based on third-party services and progress evaluations [492]. Financing Activities - Cash provided by financing activities was $34.6 million in 2025, including $19.2 million from a registered offering with ThinkEquity and $6.8 million from an ATM facility [486]. - Cash provided by financing activities was $26.7 million for the year ended December 31, 2024, including $8.2 million from warrant exercises and $14.6 million from share issuances under the ELOC Purchase Agreement [487]. Stock-Based Compensation - Stock-based compensation expense was $3.8 million for the year ended December 31, 2024, and is projected to be $1.8 million for the year ended December 31, 2025 [497]. - As of December 31, 2025, the company had $1.1 million of unrecognized stock-based compensation expense, which will be recognized over a remaining weighted-average period of 1.1 years [497]. Accounting and Regulatory Compliance - The company adopted ASU No. 2023-09 for the year ending December 31, 2025, which improves income tax disclosures [499]. - The company is evaluating the impacts of ASU 2024-03, effective after December 15, 2026, which requires additional disclosures about specific expense categories [500]. - The company has elected not to take advantage of the extended transition period for emerging growth companies, thus adhering to the same accounting standards as other public companies [501]. Fair Value and Valuation - The fair value of Common Stock Warrant Liabilities is determined using a Black-Scholes option-pricing model, which requires considerable judgment and may lead to significant differences in reported values [498]. - The assumptions used in the Black-Scholes option-pricing model for stock options include expected term, expected volatility, risk-free interest rate, and expected dividends [494][495][496].

Core Insights - Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company focused on developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1][6] - The company announced two presentations at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2026), scheduled for March 17-21, 2026, in Copenhagen, Denmark [1][2] Presentation Highlights - The presentations will showcase clinical data supporting the treatment effect of buntanetap in PD, emphasizing cognition and biomarker findings, along with an update on the ongoing pivotal Phase 3 trial in early AD [2][4] - Cheng Fang, Ph.D., Senior VP of Research & Development, expressed pride in the progress of enrollment for the Alzheimer's disease pivotal study, indicating strong engagement from investigators and patients [4] Company Overview - Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for neurodegenerative diseases, with its lead drug candidate, buntanetap, being an investigational once-daily oral therapy [6] - Buntanetap works by inhibiting the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism, aiming to halt disease progression and improve cognitive and motor functions in patients [6]

Core Viewpoint - Annovis Bio, Inc. has received a positive recommendation from an independent Data and Safety Monitoring Board (DSMB) regarding the safety of its investigational oral therapy, buntanetap, for neurodegenerative diseases, allowing the continuation of the Phase 3 clinical trial without modifications [1][3]. Group 1: Clinical Trial Progress - The DSMB reviewed safety data and recommended that the clinical trial continue as planned, with no safety concerns identified [3]. - The pivotal Phase 3 clinical trial for Alzheimer's disease (AD) is currently 40% complete, with patient recruitment ongoing across the United States [4]. - The first symptomatic efficacy readout is expected in early 2027, followed by a disease-modifying readout anticipated in early 2028 [4]. Group 2: Drug Mechanism and Company Overview - Annovis Bio is developing buntanetap, an investigational once-daily oral therapy that targets multiple neurotoxic proteins associated with neurodegenerative diseases [5]. - The company aims to halt disease progression and improve cognitive and motor functions in patients suffering from Alzheimer's disease and Parkinson's disease [5]. Group 3: Future Considerations - The FDA may consider accepting combined safety data from both Alzheimer's and Parkinson's studies for a future New Drug Application (NDA) submission [4].

Core Viewpoint - Annovis Bio, Inc. is set to launch an Open-Label Extension (OLE) study in January 2026 to assess the long-term safety and efficacy of its drug, buntanetap, in patients with Parkinson's disease [2][3] Study Overview - The OLE study aims to enroll 500 patients over a 36-month treatment period, with participants receiving a once-daily dose of 30mg oral buntanetap [9] - The study will include two cohorts: former participants of previous clinical trials and patients who have been receiving deep brain stimulation (DBS) for at least 12 months [9][10] Objectives and Methodology - The study will evaluate treatment persistence by examining how patient outcomes evolve after discontinuing treatment, providing insights into the long-term effects of buntanetap [5][6] - It will also assess patient responses when treatment is reintroduced, offering a comprehensive view of the drug's effects and durability [6] Addressing Underserved Populations - The inclusion of patients receiving DBS aims to address a gap in clinical research, as this population is often excluded due to complications in outcome assessments [8][10] - The study seeks to evaluate the interaction between buntanetap and DBS, potentially providing additional therapeutic benefits [7][10] Regulatory Advancement - The OLE study is a critical step toward a future New Drug Application (NDA) submission, helping the company meet FDA patient exposure requirements [11] - The study aims to ensure a total of approximately 1,500 treated patients, with specific targets for treatment duration and dosage [11]

Core Viewpoint - Annovis Bio, Inc. is hosting a corporate update webinar to discuss recent progress, ongoing clinical programs, and strategic directions in the development of therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2][3] Group 1: Webinar Details - The webinar will be presented by Maria Maccecchini, Ph.D., President and CEO, who will provide a comprehensive update on the company's journey and future plans [2][3] - The event is scheduled for January 28, 2026, at 4:30 p.m. ET, and is open to shareholders, patients, investigators, and other interested parties [7] - Participants are encouraged to submit questions in advance via email [3] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on developing innovative therapies aimed at improving patient outcomes in neurodegenerative diseases [4] - The company is committed to addressing conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD) [4]

Core Insights - Annovis Bio, Inc. is set to present at the 2025 Annual Meeting of the Parkinson Study Group, showcasing its advancements in therapies for neurodegenerative diseases like Alzheimer's and Parkinson's [1][5] Group 1: Presentation Highlights - The presentation will build on recent Phase 3 PD biomarker data, indicating that patients with amyloid co-pathology show significant cognitive decline, which is counteracted and reversed by the drug buntanetap [2] - A cross-study comparison of completed trials will be introduced, providing a comprehensive overview of cognitive outcomes across all tested indications, particularly highlighting the benefits for patients with amyloid pathology [3] - Findings suggest that individuals with biomarker-confirmed amyloid presence experience the greatest cognitive gains following treatment with buntanetap, validating the drug's mechanism as a translational inhibitor of neurotoxic aggregating proteins [3] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on developing innovative therapies aimed at improving outcomes and quality of life for patients suffering from neurodegenerative diseases [6] - The company is committed to advancing research and showcasing best practices in the field of Parkinson's disease [5]

Core Insights - Annovis Bio, Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative diseases, specifically Alzheimer's disease (AD) and Parkinson's disease (PD) [1][5] Group 1: Conference Presentations - Annovis will present at the 18 Clinical Trials on Alzheimer's Disease (CTAD) conference from December 1-4, 2025, in San Diego, California [1] - The presentations will emphasize progress in Alzheimer's and Parkinson's programs, particularly recent biomarker data that supports the potential disease-modifying activity of the drug buntanetap [2] Group 2: Key Findings and Statements - Maria Maccecchini, Ph.D., President and CEO of Annovis, expressed optimism about sharing findings on biomarkers and cognition, indicating that the data suggests buntanetap could address the root causes of cognitive decline [4] - The biomarker data reinforces the efficacy of buntanetap observed in earlier studies and provides a clearer path for developing effective treatments for patients in need [4] Group 3: Presentation Details - Presentation 1 will focus on "Amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson's disease dementia patients," presented by Cheng Fang, Ph.D., Senior VP, Research & Development [8] - Presentation 2 will cover a "Double 6/18-month Phase 3 study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer's disease," presented by Maria Maccecchini, Ph.D., President and CEO [8]